$1.14
0.03[2.70%]
At close: May 8
$1.14
0[0.00%]
After Hours: 6:17PM EDT
Bolt Biotherapeutics
(NASDAQ:BOLT)Latest News for Bolt Biotherapeutics Stock (NASDAQ:BOLT)
Bolt Biotherapeutics Stock (NASDAQ: BOLT)
Categories: All
Wednesday, April 03, 2024
Friday, March 22, 2024
Thursday, March 21, 2024
Tuesday, December 05, 2023
Tuesday, November 21, 2023
Thursday, November 09, 2023
Tuesday, October 17, 2023
Monday, October 02, 2023
Friday, September 29, 2023
Thursday, September 28, 2023
- Stocks That Hit 52-Week Lows On ThursdayBenzinga Insights - Sep 28, 2023, 2:32PM
- Market-Moving News for September 28thBenzinga Newsdesk - Sep 28, 2023, 8:44AM
- The FDA Has Granted Orphan Drug Designation For Bolt Biotherapeutics' BDC-1001 For Gastric Cancer, Including Gastroesophageal Junction CancerBenzinga Newsdesk - Sep 28, 2023, 7:04AM
Tuesday, September 12, 2023
Tuesday, August 22, 2023
Tuesday, August 08, 2023
Monday, August 07, 2023
Thursday, August 03, 2023
- HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $8 Price TargetBenzinga Newsdesk - Aug 3, 2023, 1:25PM
- Bolt Biotherapeutics Announced That The First Patients Have Been Dosed In Phase 2 Dose-expansion Trial Of BDC-1001 For HER2-Positive Colorectal, Endometrial, And Gastroesophageal CancersBenzinga Newsdesk - Aug 3, 2023, 7:42AM
Thursday, June 15, 2023
- Board Member at Bolt Biotherapeutics Acquires Company Stock Options Worth 25,000 SharesBenzinga Insights - Jun 15, 2023, 11:04AM
- Director at Bolt Biotherapeutics Acquires Company Stock Options Worth 25,000 SharesBenzinga Insights - Jun 15, 2023, 11:04AM
- Bolt Biotherapeutics Board Member Awarded $37K Worth of Stock OptionsBenzinga Insights - Jun 15, 2023, 11:04AM
- Bolt Biotherapeutics Director Awarded $37K Worth of Stock OptionsBenzinga Insights - Jun 15, 2023, 11:03AM
Monday, June 05, 2023
Tuesday, May 30, 2023
Friday, May 26, 2023
Friday, May 12, 2023
- Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2023Benzinga Insights - May 12, 2023, 11:00AM
- SVB Leerink Upgrades Bolt Biotherapeutics to Outperform, Announces $4 Price TargetBenzinga Newsdesk - May 12, 2023, 10:20AM
- HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $8 Price TargetBenzinga Newsdesk - May 12, 2023, 6:23AM
Wednesday, April 26, 2023
Thursday, March 30, 2023
- Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 StudiesVandana Singh - Mar 30, 2023, 11:16AM
- Looking Into Bolt Biotherapeutics's Return On Capital EmployedBenzinga Insights - Mar 30, 2023, 10:47AM
- HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $8 Price TargetBenzinga Newsdesk - Mar 30, 2023, 6:09AM
- Bolt Biotherapeutics Announces Topline Data From BDC-1001 Phase 1 Dose-Escalation Trial In HER2-Expressing Tumors, Supporting Advancement To Phase 2 Clinical StudiesHappy Mohamed - Mar 30, 2023, 1:11AM
Wednesday, March 29, 2023
Tuesday, March 28, 2023
Tuesday, March 14, 2023
Tuesday, January 24, 2023
Wednesday, December 21, 2022
Thursday, November 10, 2022
Monday, November 07, 2022
Tuesday, October 04, 2022
Thursday, August 11, 2022
- Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2022Benzinga Insights - Aug 11, 2022, 10:35AM
- SVB Leerink Cuts Price Target On This Stock By 50%, Also Check Out Some Other Major PT ChangesLisa Levin - Aug 11, 2022, 9:21AM
- SVB Leerink Downgrades Bolt Biotherapeutics to Market Perform, Lowers Price Target to $4Benzinga Newsdesk - Aug 11, 2022, 7:03AM